Scynexis (SCYX) Other Accumulated Expenses (2016 - 2026)
Scynexis' (SCYX) quarterly Other Accumulated Expenses came in at $669000.0 in Q2 2026, down 11.62% on a YoY basis from $757000.0 in Q2 2025, and down 17.31% quarter-over-quarter from $809000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Other Accumulated Expenses (2016 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Other Accumulated Expenses for 11 consecutive years, with $669000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Accumulated Expenses fell 11.62% year-over-year to $669000.0; the trailing twelve-month figure through Jun 2026 stood at $669000.0 (down 11.62% YoY), and the FY2025 full-year result was $478000.0, down 39.34% from the prior year.
- Other Accumulated Expenses declined to $669000.0 in Q2 2026 per SCYX's latest filing, from $809000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $5.8 million in Q4 2022 and bottomed at $478000.0 in Q4 2025.
- Historically, Other Accumulated Expenses has averaged $1.5 million across 5 years, with a median of $955500.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 435.34% in 2022, then sank 81.98% in 2023.
- Over 5 years, Other Accumulated Expenses stood at $5.8 million in 2022, then tumbled by 81.98% to $1.0 million in 2023, then decreased by 24.23% to $788000.0 in 2024, then tumbled by 39.34% to $478000.0 in 2025, then jumped by 39.96% to $669000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $669000.0, $809000.0, and $478000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 669,000.00 |
| Mar 31, 2026 | 809,000.00 |
| Dec 31, 2025 | 478,000.00 |
| Sep 30, 2025 | 895,000.00 |
| Jun 30, 2025 | 757,000.00 |
| Mar 31, 2025 | 942,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Sep 30, 2024 | 969,000.00 |
| Jun 30, 2024 | 862,000.00 |
| Mar 31, 2024 | 546,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 2.65 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 5.77 Mn |
| Sep 30, 2022 | 2.58 Mn |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Dec 31, 2021 | 1.08 Mn |
| Sep 30, 2021 | 2.15 Mn |